Smart Cities Market Worth 1,201.69 Bn USD by 2022
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.More to Read
MarketWise Reports Q3 Billings Increase of 27% YoY to $80.7 Million and Q3 CFFO Increase to $7.8 Million; Net Revenue of $80.1 Million and Net Income of $15.1 Million for Q3 2026; FY 2026 Dividend Target To Class A Shareholders of $1.80 Per Share
BALTIMORE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for third quarter 2026. (1) Third Quarter 2026 Highlights (1) Billings for the third quarter 2026 totaled $80.7 million, representing a 27% year-over-year increase compared to the third quarter
The Riverside Company Invests in Specialty Packaging Rental Provider, Hoover Circular Solutions
LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- An affiliate of The Riverside Company, a global investment firm focused on the smaller end of the middle market, has acquired Hoover Circular Solutions Limited (Hoover CS) from First Reserve. Headquartered in Houston, Texas, Hoover CS is a leading provider of sustainable packaging, fleet management and logistics solutions serving refining, chemical, energy and industrial customers globally. Founded in 1911, the company operates one of the industry’s
Ethos Specialty Adds Aviva Specialty to Growing Transactional Liability Capacity Panel
Expanded carrier support for Representations and Warranties Insurance and Tax Insurance solutions NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ethos Specialty Insurance Services LP (“Ethos Specialty”), a Bishop Street Underwriters company, today announced a new capacity partnership with Aviva Specialty, Aviva’s wholly owned U.S. specialty insurance platform, further strengthening its Transactional Liability business. The addition of Aviva Specialty builds on Ethos Specialty’s existing carrier rel
Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8 billion by 2030 IM8 to serve as exclusive operating partner, with Prenetics recording all Care Bears by IM8 revenue To get early access, visit www.carebearsbyIM8.com NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer healt
Bath & Body Works to Report Third Quarter Results on November 19, 2026
COLUMBUS, Ohio, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE: BBWI) announced today that it plans to report its third quarter 2026 financial results before market open on Thursday, November 19, 2026. In conjunction with this report, the company will host a conference call at 8:30 a.m. ET during which Daniel Heaf, chief executive officer, and Tom Javitch, interim chief financial officer, will discuss the company's results and provide a business update. Supplemental materials wi
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
- Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron ® reduction in pain over three months of treatment with Halneuron ® - - Closed $5M Private Placement with Sealbond Limited, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc., to Advance Phase 3 Preparatory Activities - ALPHARETTA, Ga., Nov. 05, 2026 (GLOBE NEWSWIRE)
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for potential approval in EPP anticipated by mid-2027 Feedback from the upcoming end of phase 2 meeting with the FDA on selcodebart in anemia of myelofibrosis (MF) and plans for pivotal development in anemia of MF to be announced by the end of the year Presented positive initial results from
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces Private Placement Financing of Up to $50.0 Million with Healthcare-Focused Institutional Investors – FDA Clears First-Ever IND for Peeling Skin Syndrome (PSS), Grants Rare Pediatric Disease and Fast Track Designations to QRX003 for PSS; EMA Grants Orphan Drug Designation to QRX003
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!